Table 2 Multivariate analysis for OS, Relapse and NRM.

NLR (< 2.35 vs. > 2.35)

1.33 (0.85–2.06) 0.20

0.85 (0.46–1.56) 0.6

1.27 (0.69–2.35) 0.42

MLR (< 0.31 vs. > 0.31)

0.98 (0.65–1.47) 0.93

1.51 (0.86–2.66) 0.14

0.8 (0.45–1.43) 0.46

PLR (< 133 vs. > 133)

0.56 (0.36–0.86) 0.009

0.83 (0.47–1.47) 0.53

0.61 (0.33–1.12) 0.11

DRI (low/intermediate vs. high/very high)

0.9 (0.59–1.35) 0.61

1.05 (0.61–1.81) 0.84

0.74 (0.42–1.33) 0.32

Conditioning regimen (MAC/Sequential vs. RIC)

0.53 (0.31–0.89) 0.017

0.58 (0.3–1.1) 0.09

0.56 (0.26–1.19) 0.13

GVHD prophylaxis (Alemtuzumab vs. ATG)

0.58 (0.37–0.90) 0.016

0.69 (0.37–1.29) 0.25

0.59 (0.33–1.08) 0.08

Age (< 56.7 years vs. > 56.7 years)

1.35 (0.89–2.04) 0.15

0.74 (0.43–1.26) 0.27

1.95 (1.08–3.53) 0.02

CD34 cells/kg (< 6.2 vs. > 6.2)

1.28 (0.89–1.85) 0.17

0.88 (0.54–1.45) 0.63

1.4 (0.83–2.36) 0.2

HCT-CI (1–3 vs. 4–12)

1.52 (1.04–2.21) 0.028

1.44 (0.86–2.41) 0.15

1.34 (0.79–2.27) 0.27